The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne’s Muscular Dystrophy
Open accessAbstract
We treated a 27-year-old patient with Duchenne’s muscular dystrophy (DMD) with recombinant adeno-associated virus (rAAV) serotype 9 containing dSaCas9 (i.e., “dead” Staphylococcus aureus Cas9, in which the Cas9 nuclease activity has been inactivated) fused to VP64; this transgene was designed to up-regulate cortical dystrophin as a custom CRISPR–transactivator therapy. The dose of rAAV used was 1×1014 vector genomes per kilogram of body weight. Mild cardiac dysfunction and pericardial effusion developed, followed by acute respiratory distress syndrome (ARDS) and cardiac arrest 6 days after transgene treatment; the patient died 2 days later. A postmortem examination showed severe diffuse alveolar damage. Expression of transgene in the liver was minimal, and there was no evidence of AAV serotype 9 antibodies or effector T-cell reactivity in the organs. These findings indicate that an innate immune reaction caused ARDS in a patient with advanced DMD treated with high-dose rAAV gene therapy. (Funded by Cure Rare Disease.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although AAV is substantially less inflammatory compared with many other viral vectors, treatments may require administration of high vector doses of up to 10 14 vg/ kg, in particular for applications that depend on systemic vector administration.”
From Innate immune sensing of adeno-associated virus vectors (2024) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression
Qi, L. S., Larson, M. H., Gilbert, L. A., Doudna, J. A., Weissman, J. S., Arkin, A. P., & Lim, W. A. (2013) · Cell · doi:10.1016/j.cell.2013.02.022 · Cited by 5,016
Mali, P., Aach, J., Stranges, P. B., Esvelt, K. M., Moosburner, M., Kosuri, S., Yang, L., & Church, G. M. (2013) · Nature Biotechnology · doi:10.1038/nbt.2675 · Cited by 1,752
Analysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490
Duan, D., Goemans, N., Takeda, S., Mercuri, E. M., & Aartsma-Rus, A. M. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00248-3 · Cited by 1,345
Engineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175
Effect of genome size on AAV vector packaging
Wu, Z., Yang, H., & Colosi, P. (2010) · Molecular Therapy · doi:10.1038/mt.2009.255 · Cited by 1,029
The Dystrophin Glycoprotein Complex
Lapidos, K. A., Kakkar, R. K., & McNally, E. M. (2004) · Circulation Research · doi:10.1161/01.res.0000126574.61061.25 · Cited by 534
The Dystrophin Complex: Structure, Function, and Implications for Therapy
Gao, Q. Q., & McNally, E. M. (2015) · Comprehensive physiology · doi:10.1002/cphy.c140048 · Cited by 521
Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy
Duan, D. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.011 · Cited by 489
Cited by
Sorted by citations
Items 301–320 of 320
Innate Immunocompetent hiPSC‐Derived Neurospheroids Capture Early CNS Responses to rAAV
Gomes, C. M., Silva, G., Aleixo, M. M., Gomes, M., Simão, D. F., Holtkamp, S., Lobo, D. D., Harish, P., Jenkins, R., Dahal, L. N., et al. (2026) · Advanced Science · doi:10.1002/advs.202520408
Decoding Nonlinearities in AAV-Based Gene Therapy Using PBPK Modelling
Rajwade, A., Liu, S., Kumar, M., & Shah, D. K. (2026) · The AAPS Journal · doi:10.1208/s12248-026-01285-0
Gene therapies (2015–2025): determinants of translational success
Sackett, J., Jaber, S., Gangapur, P., Biernat, M., & Bao, S. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118450
Ramadhani, E., Tsunaka, Y., Fukuhara, M., & Uchiyama, S. (2026) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2026.08.007
Advancements in CRISPR-based in vivo gene therapy for hemophilia
Zhang, X., Xu, K., Zou, S., Zhu, Z., Teng, S., & Huang, P. (2026) · Frontiers in Genome Editing · doi:10.3389/fgeed.2026.1924733
Gene therapy for rare diseases: technological innovation and clinical translation
ZHANG, Y.-J., & Yuan, H. (2026) · Shengming kexue · doi:10.3724/cbls.2026132
Gene therapy in Duchenne muscular dystrophy (DMD)
Azizsoltani, A., Ghesmati, Z., & Rezaei, E. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40467-2.00006-3
Feller, C., Young, S. C., & Gupta, K. (2026) · Human Gene Therapy · doi:10.1177/10430342261488959
Systemic responses to intravenous rAAV administration in boys with Duchenne muscular dystrophy
Harris, B. E., Seldin, B. M., Towne, S. C., Hobson, O. R., Zerpa, E., Prima, V., Sweeney, H. L., & Hammers, D. W. (2026) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2026.1953867
Kirk, R. B., Santiago, C., Watkins, H. C., & Toepfer, C. N. (2026) · Nature Cardiovascular Research · doi:10.1038/s44161-026-00884-6
Sickle cell disease-specific barriers to in vivo hematopoietic stem cell gene therapy
Choi, R., & Sheehan, V. (2026) · Seminars in Hematology · doi:10.1053/j.seminhematol.2026.09.003
Park, M. J., Kim, H.-B., Hwang, Y. C., Kim, Y.-J., Park, J.-C., Lim, H.-K., Park, Y.-G., 문성환, Lee, H., & Cha, H. (2026) · Experimental & Molecular Medicine · doi:10.1038/s12276-026-01854-5
Nano Delivery Systems for In Vivo CRISPR/Cas-Based Gene Therapy: From Vectors to Clinical Outcomes
Chen, R., Zhou, H., Wu, Q., & Gong, C. (2026) · ACS Nano · doi:10.1021/acsnano.6c12154
The global patent landscape of CRISPR–Cas applications in medicine
Yu, Y., Zhang, Y., Xu, Y., Wen, C., Li, L., & Yu, T. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03337-4
Clinical Framework for Durable Genomic Interventions
Smith, E. D., & Murthy, V. L. (2026) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2026.4690
Stage-specific Therapy for Muscular Dystrophies: From Care Standards to Gene and RNA Medicines
Choudhary, A., Kuriyal, S., chowdhury, P. H., & Baladaniya, M. (2026) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.1177/0976500x261493196
CNS targeted AAV gene therapies: Recent advances and clinical insights
Brown, B. P., Lewis, R. W., Jr., & Davidson, B. L. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103118
Li, G., Han, F., Wang, C., Jin, M., Lin, J., Zhang, H., Yan, X., Wang, X., Sun, X., Yuan, Y., et al. (2026) · Cell · doi:10.1016/j.cell.2026.09.059
Gene therapy that led to boy’s death had limited efficacy
Fieldhouse, R. (2026) · Nature · doi:10.1038/d41586-026-03449-6
Afzal, H., Rotstein, T., Biswas, D. D., Lin, X., Khodabukus, A., Luo, W., Xu, Y., Frair, E. C., 李永武, Chen, J., et al. (2026) · Cell stem cell · doi:10.1016/j.stem.2026.10.004
Metadata
- Authors
- Lek, A., Wong, B., Keeler, A., Blackwood, M., Ma, K., Huang, S., Sylvia, K., Batista, A. R., Artinian, R., Kokoski, D., Parajuli, S., Putra, J., Carreon, C. K., Lidov, H., Woodman, K., Pajusalu, S., Spinazzola, J. M., Gallagher, T., LaRovere, J., Balderson, D., Black, L., Sutton, K., Horgan, R., Lek, M., & Flotte, T.
- Affiliations
- Yale University (US)
- University of Massachusetts Chan Medical School (US)
- Boston Children's Hospital (US)
- Tartu University Hospital (EE)
- Wake Technical Community College (US)
- Charles River Laboratories (United States) (US)
- Cure Rare Disease, Woodbridge, CT, USA.
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-09-28
- Volume
- 389
- Issue
- 13
- Pages
- 1203-1210
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC11288170
- OpenAlex
- W4387077861
- Cited by
- 319
- References
- 26
- Citations by year
- 2026: 80 · 2025: 125 · 2024: 97 · 2023: 17
- FWCI
- 52.96
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute (P01HL158506)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- Duchenne muscular dystrophy, gene therapy toxicity, acute respiratory distress syndrome, cardiac arrest, diffuse alveolar damage, innate immune response, autopsy
- MeSH terms
- Adult, Antibodies, Humans, Immunity, Innate, Respiratory Distress Syndrome, Genetic Therapy, Dystrophin, Fatal Outcome, Transgenes, Muscular Dystrophy, Duchenne
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
